Anti-Microbial Resistance makes headline news once more - stay ahead at World Anti-Microbial Resistance Congress 2016

WASHINGTON, May 24, 2016 /PRNewswire/ -- It's no news that the world is facing an antibiotic crisis. Antimicrobial Resistance is probably the most serious threat the health system has faced in decades, so the field has been receiving a great deal of attention both internationally and in the US. Once again Anti-Microbial Resistance is headline news! The Review on Antimicrobial Resistance just released "Tackling drug-resistant infection globally: Final report and recommendations" which demonstrates how the world must come together in order to resolve the antibiotic crisis.

Download the preview agenda now at http://goo.gl/rCtxP1 >

With the funding from the National Action Plan and dedicated public-private partnerships such the Broad Spectrum Antimicrobial Program by the Biomedical Advanced Research and Development Authority (BARDA) and the New Drugs for Bad Bugs Program of the Innovative Medicines Initiative (IMI), there is a clear commitment to bring new antibiotics to market.

The World Anti-Microbial Resistance Congress, created by Terrapinn, taking place in Washington DC this September 8-9, is bringing together payers, funding and government agencies, academics, pharma and biotech to shine a light on this global issue and discuss potential solutions.

Download the preview agenda now at http://goo.gl/rCtxP1 >

Our expert speaking faculty includes:

• Jane Knisely, Program Officer, Bacteriology and Mycology Branch, NIAID, NIH
• Rosemarie Aurigemma, Chief, Drug Development Section, Office of Biodefense, Research Resources, and Translational Research, NIAID, NIH
• Christopher Houchens, PhD, Branch Chief (Acting), Antibacterial Program, BARDA
• Joseph Larsen, Acting Deputy Director, BARDA
• Barry Eisenstein, Distinguished Physician, Antimicrobials, Merck
• Michael Draper, Senior Director, External Science & Partnering - East Coast, Sanofi
• Kevin Outterson, Professor of Health Law, Bioethics and Human Rights, Boston University School of Law
• Robin Patel, Director, Infectious Diseases Research Laboratory, Mayo Clinic
• Thierry Bernardi, Founder, Biofilm Control
• David Shlaes, Founder, Antibiotics – The Perfect Storm
• Jean Patel, Deputy Director, Office of Antimicrobial Resistance, CDC
• Ed Pezalla, Vice President, National Medical Director for Pharmaceutical Policy and Strategy, Aetna
• Stefano Bertuzzi, Executive Director/CEO, American Society for Microbiology (confirmed)
• François Jehl, Bacteriology Lab manager, Hospital Strasbourg, France, French Committee Antibiogram Susceptibility Test coordinator
• Frédéric Laurent, Professor of Microbiology, National Reference Center on Staphylococcus, Hospital Lyon, France
• Fabrizio Ensoli,  Sapienza University of Roma, Italy
• Prabhavathi Fernandes, Chief Executive Officer, Cempra
• Dave Mantus, Chief Development Officer, Arsanis
• Anders Karlén, Professor, Department of Organic Pharmaceutical Chemistry, Biomedical Centre, Uppsala University, Leader, Managing Entity, ENABLE

Download the preview agenda now at http://goo.gl/rCtxP1 > 

SOURCE Terrapinn Inc.

Related Links

http://www.terrapinn.com